Catalent

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

CTLT reports Q3 revenue decline, eyes growth in gene therapy

CTLT faced challenges in the Biologics segment and adjusted its fiscal 2023 guidance due to operational and COVID-related issues. However, the company's capacity and healthy pipeline in the gene therapy business present opportunities for growth. The company is also evaluating divestitures to reduce debt load and is focused on improving financial rigor in the upcoming fiscal year.

Catalent reports solid Q2 earnings, eyes gene therapy expansion

Catalent's Q2 performance was solid, with a focus on collaborations, ESG initiatives, and strong market positioning. Challenges in the supply chain and COVID revenue assumptions were notable, but opportunities in gene therapy and core business growth are promising. The company remains optimistic about future growth and strategic partnerships.

Catalent adjusts guidance, targets cost savings amid operational challenges

Catalent focused on improving productivity and cost structure to return to historical margin levels.
Addressing investor concerns on regulatory inspections and confident in corrective actions.
Expecting significant cost savings in fiscal '24 and targeting positive cash generation.
Operational challenges in Q3 impacting financials in Q4, with a focus on improving profitability.

Catalent addresses challenges, eyes growth in gene therapy and GLP-1

Catalent navigated fiscal challenges, focusing on growth areas like gene therapy and GLP-1 projects. The company aims to address financial performance, operational efficiency, and strategic reviews to enhance shareholder value and sustain growth.

Catalent reports solid Q1 performance amidst revenue challenges and growth opportunities

Catalent's Q1 performance was solid despite revenue decline from COVID.
The company is focusing on growth drivers like gene therapy and GLP-1 demand.
Challenges include revenue concentration risks and capacity constraints.
Opportunities lie in new business wins, tech transfer completion, and strategic improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Catalent (NYSE:CTLT) rose 2.7% in pre-market trading after the company reported Q4 results.

Catalent: Q4 Earnings Insights

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc.

Catalent, Inc. Reports Fourth Quarter Fiscal 2020 Results

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalent (CTLT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Catalent Signs Agreement with AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine AZD1222

Catalent, Inc. Announces Preliminary Unaudited Fourth Quarter and Full Fiscal Year 2020 Net Revenue, Earnings Before Income Taxes, and Adjusted EBITDA Significantly Ahead of Its Previous Guidance

AstraZeneca

BioNTech SE

Emergent BioSolutions

Johnson & Johnson

Lonza Group AG

Moderna

Novavax

Pfizer

The Race To Erase COVID-19

Humanigen Expands Partnership with Catalent Biologics to Manufacture Investigational COVID-19 Therapeutic Candidate Lenzilumab

This company will make money from Moderna's COVID-19 vaccine even if Moderna doesn't.

Is This Under-the-Radar Stock a Better Coronavirus Play Than Moderna?

FactSet Research Systems

iShares S&P Mid-Cap 400 Growth ETF

Bullish chart patterns suggest that the the mid-cap growth market segment is worth watching over the weeks and months ahead.

Charts Suggest Mid-Cap Growth Stocks Are Headed Higher

Moderna (MRNA) teams up with Catalent for large-scale, commercial fill-finish manufacturing of the former's mRNA-based COVID-19 vaccine candidate.

Moderna Collaborates With Catalent for Coronavirus Vaccine

Moderna Inc (NASDAQ: MRNA), a frontrunner in the COVID-19 vaccine race, announced a manufacturing collaboration agreement Thursday with contract development and manufacturing organization Catalent Inc (NYSE: CTLT).

Moderna, Catalent Collaborate On Coronavirus Vaccine Manufacturing Capacity

Moderna Inc said on Thursday it was partnering with contract drugmaker Catalent Inc to prepare an initial 100 million doses of its coronavirus vaccine for the United States, starting in the third quarter of this year.

Moderna eyes third quarter for first doses of potential COVID-19 vaccine with Catalent deal

Moderna Inc said on Thursday it was partnering with contract drugmaker Catalent Inc for filling and packaging millions of doses of its experimental coronavirus vaccine to be supplied in the United States.

Moderna picks drugmaker Catalent to manufacture potential COVID-19 vaccine

Shares of Moderna Inc. MRNA, +3.01% gained 2.6% in premarket trading on Thursday after the company said that Catalent Inc.

Shares of Moderna, Catalent gain on vaccine manufacturing deal

CAMBRIDGE, Mass. & SOMERSET, N.J.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a collaboration for l

Moderna and Catalent Announce Collaboration for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate

The contract manufacturer will be able to supply hundreds of millions of doses of AZD1222 starting in August.

Catalent to Mass-Produce a Coronavirus Vaccine for AstraZeneca and Oxford University

A combination of acquisitions and coronavirus vaccine manufacturing deals have pushed shares to an all-time high, but not all earnings are flowing to common stockholders.

Is Catalent a Buy?

Catalent, Inc. (CTLT) CEO John Chiminski on Q3 2020 Results - Earnings Call Transcript

It helps that the current fiscal year concludes at the end of June, but the business also remains an essential partner for the pharmaceutical industry.

Catalent Expects to Finish Fiscal 2020 Strong Amid Coronavirus Pandemic

Gilead Sciences

GlaxoSmithKline

Vir Biotechnology

Around 70 companies are working on coronavirus treatments. Here are a few with the most promise.

Finding a Coronavirus Cure: 5 Companies Making Moves

Catalent (CTLT) delivered earnings and revenue surprises of 2.04% and 10.18%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Q3 Earnings and Revenues Beat Estimates

Arcturus Therapeutics

SAN DIEGO and SOMERSET, N.J., May  04, 2020  (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“Arcturus”, “the Company”, Nasdaq: ARCT), a leading clinical-stage messenger RNA (mRNA) medicines and vaccines company, and Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a partnership to support the expected manufacture of Arcturus’ COVID-19 mRNA vaccine candidate (LUNAR-COV19), intended to protect against the SARS-CoV-2 coronavirus.

Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine

Pacira Pharmaceuticals

PCRX vs. CTLT: Which Stock Is the Better Value Option?

PCRX or CTLT: Which Is the Better Value Stock Right Now?

Catalent expects to be ready to manufacture the drug giant's lead COVID-19 vaccine by January.

Catalent and Johnson & Johnson Sign Coronavirus Vaccine Manufacturing Deal

Catalent (CTLT) Reports Next Week: What to Expect

News for Catalent Stock (CTLT)